Shareholder Reductions - Liu Xiaoying of Huason Pharmaceutical plans to reduce holdings by no more than 3% [1] - Dazi Yintai of Wushang Group plans to reduce holdings by no more than 3% [1] - The controlling shareholder of Runbei Hangke intends to collectively reduce holdings by no more than 3% [1] - Zhao Dongri of Rike Chemical plans to reduce holdings by no more than 3% [1] - Guo Yongfang of Guotou Intelligent plans to reduce holdings by 859.47 million shares [1] - Liu Chengyan, a director of Wangsu Technology, plans to reduce holdings by no more than 1.07% [1] - Dashu Chengzhang of Guoke Tiancai plans to reduce holdings by no more than 3% [1] - Sun Wenqiang, chairman of Haitai Technology, plans to reduce holdings by no more than 3% [1] - Baolifeng of Magu Technology plans to reduce holdings by no more than 214.96 million shares [1] - Zhang Mingyuan of Shunna Co., Ltd. plans to reduce holdings by no more than 1% [1] - Hengdian Holdings plans to reduce 964.40 million shares of Hengdian East Magnetic [1] - Tai'an Hahe has cumulatively reduced 157.2 million shares of Haimeixing [1] - The National Integrated Circuit Fund has reduced 1.08% of Yandong Micro's shares [1] Other Developments - ST Xinhua Jin faces potential suspension risk as the deadline for fund occupation rectification approaches [1] - Minglida has terminated the investment in the construction of the Zhaoqing new energy key component intelligent manufacturing project [1]

Core Viewpoint - On February 10, no A-share listed companies disclosed any increase in shareholding, while nine companies announced share reductions [1]. Group 1: Companies with Share Reductions - Fenghuo Communication: Some directors and executives plan to reduce holdings by no more than 348,300 shares [2]. - Huayi Group: Senior management member Gu Chunlin intends to reduce holdings by no more than 0.006% of shares [2]. - Wangsu Science and Technology: Director Liu Chengyan plans to reduce holdings by no more than 1.07% of shares [2]. - Rike Chemical: Shareholder Zhao Dongri intends to reduce holdings by no more than 3% of shares [2]. - Haitai Technology: Controlling shareholder Sun Wenqiang plans to reduce holdings by no more than 3% of shares [2]. - Wunan Group: Shareholder Dazi Yintai intends to reduce holdings by no more than 3% of shares [2]. - Weifeng Technology: Shareholder Pingyang Weishi Investment plans to reduce holdings by no more than 2.98% of shares [2]. - Runbei Aerospace: Shareholders plan to collectively reduce holdings by no more than 3% of shares [2]. - Huason Pharmaceutical: Shareholder Liu Xiaoying intends to reduce holdings by no more than 3% of shares [2].

Group 1 - The core point of the article is that Liu Xiaoying plans to reduce her shareholding in Huasen Pharmaceutical (002907) by a total of up to 12.52 million shares, which represents a maximum of 3% of the company's total share capital [2][3] Group 2 - Liu Xiaoying currently holds 35.8947 million shares of the company [2] - The planned reduction includes a maximum of 4.176 million shares through centralized bidding, not exceeding 1% of the total share capital [2] - Additionally, up to 8.3519 million shares may be sold through block trading, not exceeding 2% of the total share capital [2]

Core Viewpoint - Huason Pharmaceutical (002907.SZ) announced that Ms. Liu Xiaoying plans to reduce her shareholding in the company through various methods over the next three months [1] Summary by Categories Shareholding Reduction Plan - Ms. Liu Xiaoying intends to reduce her holdings by up to 1% of the total share capital through centralized bidding within 15 trading days from the announcement date [1] - Additionally, she plans to reduce up to 2% of the total share capital through block trading [1] - The total reduction will not exceed 3% of the company's total share capital [1]

Core Viewpoint - The major shareholder Liu Xiaoying of Huason Pharmaceutical plans to reduce her holdings due to personal financial needs, with a total potential reduction of up to 12.52 million shares, representing 3% of the company's total share capital [1] Group 1 - Liu Xiaoying holds 35.8947 million shares, which accounts for 8.6% of the total shares [1] - The planned reduction includes a maximum of 4.176 million shares through centralized bidding, not exceeding 1% of the total share capital [1] - Additionally, a maximum of 8.3519 million shares will be reduced through block trading, not exceeding 2% of the total share capital [1]

Group 1 - The core point of the article is that Liu Xiaoying plans to reduce her shareholding in Huason Pharmaceutical, with specific limits on the number of shares to be sold [1] - Liu Xiaoying holds approximately 35.89 million shares of the company and intends to sell up to about 4.18 million shares through centralized bidding, which is no more than 1% of the total share capital [1] - Additionally, she plans to sell up to about 8.35 million shares through block trading, representing no more than 2% of the total share capital, leading to a total potential reduction of up to approximately 12.53 million shares, or 3% of the total share capital [1]

证券代码：002907 证券简称：华森制药 公告编号：2026-006 重庆华森制药股份有限公司 关于公司持股5%以上股东减持股份预披露的公告 公司持股5%以上的股东刘小英女士保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信 息一致。 特别提示： 重庆华森制药股份有限公司（以下简称"公司"）于近日收到刘小英女士发来 的《关于计划减持公司股份的告知函》。持有公司35,894,679股股份的刘小英女士 计划自本公告披露之日起至15个交易日届满次日起的3个月内通过集中竞价方式减 持公司股份不超过4,175,963股，不超过公司总股本的1%；通过大宗交易方式减持 公 司 股 份 不 超 过8,351,926 股 ， 不 超 过 公 司 总 股 本 的2% ； 合 计 减 持 不 超 过 12,527,889股，即不超过公司总股本的3%。 一、股东的基本情况 | 股东名称 | 股东性质 | 持股数量（股） | 占公司总股本比例 | | --- | --- | --- | --- | | | | | （%） | | 刘小英 | ...

Core Viewpoint - The announcement details the share reduction plans of Huason Pharmaceutical's controlling shareholders, indicating significant changes in ownership structure and potential impacts on stock performance [1][2]. Share Reduction Plans - The controlling shareholder, You Hongtao, plans to reduce his holdings by up to 6,649,826 shares, representing 1.59% of the total share capital, through block trading from November 6, 2025, to February 5, 2026 [1]. - Shanghai Tiancheng Investment Management Co., Ltd. plans to reduce its holdings by a total of 5,878,000 shares, which is 1.41% of the total share capital, through both centralized bidding and block trading during the same period [1][2]. Reduction Results - As of February 5, 2026, You Hongtao reduced 5,965,965 shares at an average price of 14.18 yuan per share, while the Tiancheng Fund reduced 1,429,480 shares at an average price of 15.64 yuan per share, totaling 7,395,445 shares and approximately 107 million yuan in cash [2][3]. Shareholder Structure - You Hongtao is one of the actual controllers of Huason Pharmaceutical and is also the chairman and general manager. The actual controllers include You Yizhu, You Hongtao, and Wang Ying, with a combined holding of 68.00% as of June 30, 2025 [4]. Previous Reductions - Chengdu Local Construction Machinery Engineering Co., Ltd. previously reduced its holdings by 12,527,826 shares, accounting for 3.00% of the total share capital, with a cash inflow estimated between 194 million yuan and 216 million yuan [5].

Group 1 - The company Huason Pharmaceutical announced on February 6 that it received a notification letter regarding the share reduction from shareholders You Hongtao and the Tiancheng Tianli No. 1 Fund [1] - The shareholders reduced their holdings by approximately 7.4 million shares, which accounts for 1.77% of the company's total shares [1]

重庆华森制药股份有限公司 关于公司控股股东一致行动人减持时间届满暨减持结果 公告 公司控股股东一致行动人游洪涛先生、上海添橙投资管理有限公司 －添橙添利一号私募证券投资基金保证向本公司提供的信息内容真实、 证券代码：002907 证券简称：华森制药 公告编号：2026-005 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信 息一致。 重庆华森制药股份有限公司（以下简称"公司"）于 2025 年 10 月 15 日发 布《关于公司控股股东一致行动人减持股份预披露的公告》（公告编号：2025- 078），游洪涛先生计划自前述公告披露之日起 15 个交易日后的 3 个月内（即 2025 年 11 月 6 日至 2026 年 2 月 5 日）通过大宗交易方式减持公司股份合计不 超过 6,649,826 股，占公司总股本的 1.59%。上海添橙投资管理有限公司－添 橙添利一号私募证券投资基金（下称"添橙添利一号基金"）计划自前述公告 披露之日起 15 个交易日后的 3 个月内（即 2025 年 11 月 6 日至 2026 年 2 月 5 日）通过集中竞价方式减持公司股份不超过 4,175,900 股，占公 ...